[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596274":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":31,"responsibleParty":52,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":25,"overallStatus":34,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","Group 1 (coasting only): In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.",[13],"Procedure: Coasting",{"label":15,"type":10,"description":16,"interventionNames":17},"Cabergoline group","Coasting plus cabergoline: In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.",[13,18],"Drug: Cabergoline",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Coasting","In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.",[15,9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DRUG","Cabergoline","Cabergoline is used to treat different types of medical problems that occur when too much of the hormone prolactin is produced. It can be used to treat certain menstrual problems, fertility problems in men and women, and pituitary prolactinomas",[15],[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Mostafa Bahaa","RECRUITING","Damietta","New Damietta","34518","Egypt","EG",{"type":41,"coordinates":42},"Point",[43,44],31.81332,31.41648,{"lat":44,"lon":43},[47],{"name":48,"role":49,"phone":50,"phoneExt":25,"email":51},"Mostafa Bahaa, PhD","CONTACT","0201025538337","mbahaa@horus.edu.eg",{"type":53,"investigatorFullName":33,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Lecturer","100596274","phase-2-clinical-study-to-evaluate-efficacy-of-cabergoline-to-coasting-in-reducing-the-incidence-of-ovarian-hyperstimulation-syndrome-100596274",false,"NCT07043322","Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome","Inclusion Criteria:\n\n* Age between 18-38 years\n* Body mass index (calculated as weight in kilograms divided by the square of height in meters) \\\u003C 30 kg\u002Fm2.\n* A long luteal protocol is used for ovarian stimulation.\n* Day 2 FSH \\\u003C10 mIU\u002FL and E2\\\u003C 50 pg\u002Fml\n* High risk of OHSS, defined as having more than 20 follicles \\>12 mm in diameter and\u002For E2 levels \\> 3000 pg\u002Fml when the size of the leading follicle is \\> 15 mm\n\nExclusion Criteria:\n\nThe presence of chronic medical diseases, including liver cell failure, renal failure, uncontrolled hypertension, uncontrolled diabetes mellitus, or class 3 or 4 function heart disease in the New York heart association classification.\n\nAllergy to Cabergoline.","FEMALE","20 Years","35 Years",{"count":65,"type":66},150,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of controlled ovarian stimulation of gonadotrophin-Stimulated ovarian cycles. It is theorized to manifest systemically as a result of vasoactive mediators like vascular endothelium growth factor (VEGF) being released from hyperstimulated ovaries. As a result, capillary permeability is increased which causes the extravasation of fluid from the intravascular compartment into the third space. The haemoconcentration which ensues results in complications such as hypercoagulability and reduced end organ perfusion.",[72],"Gynecologic Disease","2026-03-12",{"date":75,"type":76},"2026-03-13","ACTUAL",{"date":78,"type":76},"2025-06-30",{"date":80,"type":66},"2026-11-20",{"name":5,"class":6},1]